SRPTSarepta Therapeutics, Inc.

1. Sep 23, 2026On September 23, 2026 (the “Effective Date”), Sarepta Therapeutics, Inc. (the “Company”), Sarepta Therapeutics Three, LLC (“Sarepta Three” and, together with the Company, “Sarepta”), REGENXBIO Inc. (“REGENXBIO”), the Trustees of the University of Pennsylvania (“UPenn”) and Catalent, Inc. (“Catalent”) entered into a …Material agreement entered · Form 8-K
2. Aug 5, 2026Sarepta Therapeutics Announces Second Quarter 2026 Financial Results and Recent Corporate Developments.Earnings release · press release
3. Jul 27, 2026On July 23, 2026, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) appointed Michael Severino, M.D. as Chief Executive Officer of the Company, effective July 28, 2026 (the “Effective Date”)Director or officer change · Form 8-K
4. Jun 4, 2026On June 4, 2026, Sarepta Therapeutics, Inc. (the “Company”) held its annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, the Company’s stockholders voted to approve the Company’s 2026 Equity Incentive Plan (the “2026 Plan”)Director or officer change · Form 8-K
5. May 6, 2026Sarepta Therapeutics Announces First Quarter 2026 Financial Results and Recent Corporate Developments.Earnings release · press release
6. Feb 25, 2026On February 25, 2026, Douglas Ingram notified Sarepta Therapeutics, Inc. (the “Company”) of his decision to retire as Chief Executive Officer by the end of 2026 or upon the appointment of his replacement.Director or officer change · Form 8-K
7. Feb 25, 2026Sarepta Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Recent Corporate Developments.Earnings release · press release
8. Jan 12, 2026Sarepta Reports Preliminary* Fourth Quarter and Full-Year 2025 Net Product Revenues.Earnings release · press release
9. Dec 19, 2025As previously announced, on December 10, 2025, Sarepta Therapeutics, Inc. (the “Company”) entered into separate, privately negotiated exchange agreements (the “Exchange Agreements”) with certain holders of its 1.25% Convertible Senior Notes due 2027 (the “Existing Convertible Notes”), including the Michael A. Chambers …Material agreement entered · Form 8-K
10. Dec 11, 2025On December 11, 2025, the Company issued a press release announcing the Exchange.Unregistered sale of equity · Form 8-K
11. Dec 8, 2025On December 7, 2025, the Board of Directors (the “Board”) of Sarepta Therapeutics, Inc. (the “Company”) granted equity awards to Douglas S. Ingram, the Company’s Chief Executive Officer, under the Company’s 2018 Equity Incentive Plan (the “Plan”)Director or officer change · Form 8-K
12. Nov 3, 2025Sarepta Therapeutics Announces Third Quarter 2025 Financial Results and Recent Corporate Developments, Including Completion of Its Confirmatory Study, ESSENCE.Earnings release · press release

Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.